Clinical pharmacology of opioids for pain

被引:360
作者
Inturrisi, CE [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA
关键词
analgesic; endogenous opioid; euphoria; morphinelike agonist; opioid receptor; opioid rotation;
D O I
10.1097/00002508-200207001-00002
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The pharmacological effects of the opioid analgesics are derived from their complex interactions with three opioid receptor types (mu, delta, and kappa; morphine is an agonist at the mu opioid receptor). These receptors are found in the periphery, at presynaptic and postsynaptic sites in the spinal cord dorsal horn, and in the brain stem, thalamus, and cortex, in what constitutes the ascending pain transmission system, as well as structures that comprise a descending inhibitory system that modulates pain at the level of the spinal cord. The cellular effects of opioids include a decrease in presynaptic transmitter release, hyperpolarization of postsynaptic elements, and disinhibition. The endogenous opioid peptides are part of an endogenous pain modulatory system. A number of opioids are available for clinical use, including morphine, hydromorphone, levorphanol, oxymorphone, methadone, meperidine, oxycodone, and fentanyl, and their advantages and disadvantages for the management of pain are discussed. An understanding of the pharmacokinetic properties, as well as issues related to opioid rotation, tolerance, dependence, and addiction are essential aspects of the clinical pharmacology of opioids for pain.
引用
收藏
页码:S3 / S13
页数:11
相关论文
共 43 条
[1]  
*AM PAIN SOC, 1999, PRINC AN US TREATM A
[2]   Accuracy in equianalgesic dosing: Conversion dilemmas [J].
Anderson, R ;
Saiers, JH ;
Abram, S ;
Schlicht, C .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 21 (05) :397-406
[3]  
[Anonymous], 1994, AHCPR PUBLICATION
[4]  
[Anonymous], 2001, Goodman Gilman's
[5]  
Bennett GJ, 2000, J PAIN SYMPTOM MANAG, V19, pS2
[6]  
Bruera E, 1997, PROG PAIN RES MANAG, V8, P717
[7]  
Caruso FS, 2000, J PAIN SYMPTOM MANAG, V19, pS31
[8]  
Davis AM, 1999, J PHARMACOL EXP THER, V289, P1048
[9]   Methadone in cancer pain management: Individualize dose and titrate to effect [J].
Foley, KM ;
Houde, RW .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3213-3215
[10]  
FOLEY KM, 1996, CECIL TXB MED, P100